Company profile
HUTCHMED (China) Ltd
NASDAQ:HCMBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Sovleplenib | phase3 | — | 14 | active |
| Amdizalisib | phase2 | — | 5 | completed, terminated |
| Ranosidenib | phase1 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (115)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03903705 | phase1_2 | completed | 2019-04-25 | 2023-11-15 | Hutchmed | : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
| NCT06387082 | phase1 | recruiting | 2024-05-27 | 2027-10-08 | Hutchmed | A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
| NCT05318820 | — | completed | 2022-06-01 | 2022-07-31 | Hutchison Medipharma Limited | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers |
| NCT02590965 | phase2 | completed | 2014-05-29 | 2015-08-07 | Hutchison Medipharma Limited | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer |
| NCT02966171 | phase1 | terminated | 2017-01-01 | 2018-08-23 | Hutchison Medipharma Limited | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies |
FDA applications (0)
No records yet.